amifostine anhydrous has been researched along with Hepatoblastoma in 5 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Hepatoblastoma: A malignant neoplasm occurring in young children, primarily in the liver, composed of tissue resembling embryonal or fetal hepatic epithelium, or mixed epithelial and mesenchymal tissues. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The primary objective was to assess the efficacy of any medical intervention to prevent hearing loss in children with cancer treated with platinum-based therapy (that is including cisplatin, carboplatin and/or oxaliplatin) when compared to placebo, no additional treatment or a different protective medical intervention." | 4.90 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2014) |
| "At the moment there is no evidence from individual studies in children with osteosarcoma and hepatoblastoma treated with different platinum analogues and dosage schedules which underscores the use of amifostine as an otoprotective intervention as compared to no additional treatment." | 2.48 | Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. ( van As, JW; van Dalen, EC; van den Berg, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van As, JW | 2 |
| van den Berg, H | 2 |
| van Dalen, EC | 2 |
| Katzenstein, HM | 1 |
| Chang, KW | 1 |
| Krailo, M | 2 |
| Chen, Z | 1 |
| Finegold, MJ | 1 |
| Rowland, J | 1 |
| Reynolds, M | 1 |
| Pappo, A | 1 |
| London, WB | 1 |
| Malogolowkin, M | 1 |
| Sullivan, MJ | 1 |
| Anderson, JR | 1 |
2 reviews available for amifostine anhydrous and Hepatoblastoma
| Article | Year |
|---|---|
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2014 |
Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
Topics: Adolescent; Amifostine; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Child; Child, Preschool; | 2012 |
1 trial available for amifostine anhydrous and Hepatoblastoma
| Article | Year |
|---|---|
Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Ci | 2009 |
2 other studies available for amifostine anhydrous and Hepatoblastoma
| Article | Year |
|---|---|
Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.
Topics: Amifostine; Cisplatin; Clinical Trials as Topic; Hearing Loss; Hepatoblastoma; Humans; Infant; Inter | 2009 |
The Children's Oncology Group routinely applies "lack of efficacy" interim monitoring to its randomized clinical trials.
Topics: Amifostine; Child; Clinical Trials Data Monitoring Committees; Clinical Trials, Phase III as Topic; | 2011 |